|19.53||+0.2500||+1.30%||Vol 99.36K||1Y Perf 25.26%|
|Apr 13th, 2021 15:53 DELAYED|
|- -%||- -|
|Target Price||-||Analyst Rating||— — 0.00|
|Potential %||-||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Market Cap||444.50M||Earnings Rating||—|
|Price Range Ratio 52W %||57.27||Earnings Date||-|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||103.79K|
|Avg. Monthly Volume||89.00K|
|Avg. Quarterly Volume||87.11K|
TeklaLife Sciences Investors (NYSE: HQL) stock closed at 19.28 per share at the end of the most recent trading day (a -1.28% change compared to the prior day closing price) with a volume of 154.36K shares and market capitalization of 444.50M. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Asset Management industry, Financial Services sector and employs 0 people. TeklaLife Sciences Investors CEO is .
The one-year performance of TeklaLife Sciences Investors stock is 25.26%, while year-to-date (YTD) performance is -2.38%. HQL stock has a five-year performance of 0.16%. Its 52-week range is between 15.79 and 22.32, which gives HQL stock a 52-week price range ratio of 57.27%
TeklaLife Sciences Investors currently has a PE ratio of 3.80, a price-to-book (PB) ratio of 0.96, a price-to-sale (PS) ratio of 5.01, a price to cashflow ratio of 17.30, a PEG ratio of 2.32, a ROA of 28.25%, a ROC of -% and a ROE of 28.38%. The company’s profit margin is 99.46%, its EBITDA margin is -%, and its revenue ttm is $93.37 Million , which makes it $3.85 revenue per share.
Of the last four earnings reports from TeklaLife Sciences Investors, there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. TeklaLife Sciences Investors’s next earnings report date is -.
The consensus rating of Wall Street analysts for TeklaLife Sciences Investors is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for TeklaLife Sciences Investors stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
TeklaLife Sciences Investors has a dividend yield of 8.17% with a dividend per share of $1.58 and a payout ratio of 407.00%.
TeklaLife Sciences Investors has a Sell technical analysis rating based on Technical Indicators (ADX : 14.48, ATR14 : 0.62, CCI20 : -115.32, Chaikin Money Flow : -0.28, MACD : -0.35, Money Flow Index : 41.82, ROC : -1.98, RSI : 36.86, STOCH (14,3) : 0.00, STOCH RSI : 0.52, UO : 28.04, Williams %R : -100.00), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of TeklaLife Sciences Investors in the last 12-months were:
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.